Zoetis ZTS - 15% Yearly Returns For The Next 15 Years?
Summary
Sven provides an in-depth analysis of Zoetis, highlighting its status as a leader in the animal health pharmaceutical industry. Sven notes that the stock has recently fallen, catching the attention of investors like Michael Burry, who views it as a 'fat pitch' with the potential for 15% annual returns over the next 15 years. Sven explains that the market is an oligopoly with high barriers to entry, which supports the company's high return on invested capital and strong margins.
Sven discusses the company's financial strategy, noting that while Wall Street is concerned about short-term uncertainty in the US market, Zoetis continues to generate approximately $2 billion in annual cash flow. Sven points out that the management is focused on shareholder returns, utilizing both dividends and share buybacks, even taking on debt to repurchase shares when they believe the stock is undervalued. Sven estimates that even with conservative growth assumptions of 7%, the addition of buybacks and dividends could lead to total annual returns of around 12%.
Mentioned Stocks
Reasoning: Sven considers Zoetis a high-quality value play due to its oligopolistic market position and high return on capital. Sven notes that a P/E ratio of 12 is very attractive for a company with 10% expected market growth and strong cash flows of $2 billion. Sven believes the combination of dividends, organic growth, and share buybacks creates a path to 12% or higher annual returns, making it an excellent risk-reward opportunity following its recent price drop.